This may be explained by the different cells used in the experiments (K562G CML cell line vs primary CD34 + CML and Ph + ALL), implying that the action of KPT-330 might be cell-type dependent. The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.